البحث العلمي في دولة الإمارات

Managing MS Treatment During Family Planning

نُشرت في السبت، 20 يونيو 2020

Disease-Modifying Drugs and Family Planning in People with Multiple Sclerosis: A Consensus Narrative Review from the Gulf Region

Managing multiple sclerosis (MS) during pregnancy poses challenges due to the risks of disease-modifying drugs (DMDs). Gulf-based experts recommend continuing safer treatments like interferon β, glatiramer acetate, and, in specific cases, natalizumab until 30 weeks of gestation. Immune reconstitution therapies, like cladribine and alemtuzumab, require planning due to prolonged washout periods. Interferon β is also deemed safe for breastfeeding. Experts highlight the need for individualized approaches to balance disease activity management and family planning while addressing data gaps for certain DMDs during breastfeeding.

البحوث ذات الصلة

اعرف المزيد
Switching from Fingolimod/Natalizumab to Cladribine Without Rebound
الجمعة، 1 ديسمبر 2023

Switching from Fingolimod/Natalizumab to Cladribine Without Rebound

اعرف المزيد
اعرف المزيد
Adherence Challenges for High-Efficacy MS Therapies
الجمعة، 22 مايو 2020

Adherence Challenges for High-Efficacy MS Therapies

اعرف المزيد
اعرف المزيد
Living with MS: A Biopsychosocial Perspective
الثلاثاء، 17 أغسطس 2021

Living with MS: A Biopsychosocial Perspective